The hottest new area of medicine today is a cutting-edge technology that leverages the body’s own cells to treat disease.
Companies have been pouring in and investing billions. But they’re encountering one big challenge: actually making the treatments.
New gene and cell therapies are encountering years-long backlogs, and delays keep potentially lifesaving medicines away from patients.
Visit BusinessInsider.com for more stories.
For the biotech company Meira Gtx, a 29,000-square-foot factory in central London is the solution to a problem that has bedeviled its entire industry.
The $660 million startup develops cutting-edge gene therapies, which tinker with the body’s DNA in hopes of treating serious illnesses. Meira focuses on a number of diseases of the eye, salivary gland and brain.
The company had only just started in 2015 when a huge opportunity opened up, to lease a drug manufacturing facility from a leading UK eye hospital. Meira jumped at it, quickly hiring pharma veterans to build out its capabilities and take over manufacturing, snapping up its new head of quality from the Swiss drug giant Novartis.
Gene therapy is the hottest area in medicine, offering up the potential to treat or even cure devastating rare …read more
Source:: Businessinsider – Finance